Comparing Evenity vs Jubbonti
| Evenity (romosozumab) | Jubbonti (denosumab) |
|
|---|
| Evenity (romosozumab) | Jubbonti (denosumab) |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Osteoporosis. Evenity may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Osteoporosis. Jubbonti may also be used for purposes not listed in this medication guide. |
Related suggestions Osteoporosis
|
|||||||
| More about Evenity (romosozumab) | More about Jubbonti (denosumab) | ||||||||
| Ratings & Reviews | |||||||||
|
Evenity has an average rating of 6.6 out of 10 from a total of 79 ratings on Drugs.com. 48% of reviewers reported a positive effect, while 18% reported a negative effect. |
Be the first to share your experience with this drug. |
||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||
View all Evenity side effects |
View all Jubbonti side effects |
||||||||
| Drug Class | |||||||||
| Generic Availability | |||||||||
|
N/A |
N/A |
||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||
View all Evenity prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
| Dosage Forms | |||||||||
|
N/A |
||||||||
| Brand Names | |||||||||
|
N/A |
Other denosumab brands include: Bomyntra, Conexxence, Osenvelt, Ospomyv, Prolia, Stoboclo, Wyost, Xbryk, Xgeva View more | ||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||
|
307.2 hours |
609.6 hours |
||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | |||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Category X
Not for use in pregnancy
See the full pregnancy warnings document. |
||||||||
| Drug Interactions | |||||||||
|
A total of 48 drugs are known to interact with Evenity:
|
A total of 308 drugs are known to interact with Jubbonti:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
| Disease Interactions | |||||||||
| First Approval Date | |||||||||
|
April 09, 2019 |
March 05, 2024 |
||||||||
| WADA Class View classifications | |||||||||
|
N/A |
N/A |
||||||||
| More Information | |||||||||
| Patient Resources | |||||||||
| Professional Resources | |||||||||
|
N/A |
|||||||||
| Related Treatment Guide | |||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Prolia
Prolia (denosumab) is an injection that is administered subcutaneously (under the skin) once every ...
Fosamax
Fosamax (alendronate) is used to treat or prevent postmenopausal osteoporosis and steroid-induced ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Premarin
Premarin is used to treat symptoms of menopause such as hot flashes, and vaginal dryness. Learn ...
Reclast
Reclast (zoledronic acid) is used to treat osteoporosis in women after menopause and also to treat ...
Zometa
Zometa is used to treat high blood levels of calcium caused by cancer and multiple myeloma. Learn ...
Boniva
Boniva (ibandronate) is used to treat or prevent osteoporosis in women after menopause. Includes ...
Atelvia
Atelvia (risedronate) is used to treat osteoporosis in women after menopause. Includes Atelvia side ...
Xgeva
Xgeva prevents bone fractures and other skeletal conditions in people with multiple myeloma, and is ...
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.